PTGX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$178.21median target· current $128.75 (+38.4%)13 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio125.00Forward 36.90
EPS (TTM)$1.03351.3% YoY
Profit margin29.4%HEALTHCARE
Market cap$8.33BMid cap
Valuation
- Forward P/E
- 36.90
- PEG ratio
- 0.00
- P/B
- 10.67
- P/S (TTM)
- 29.54
- EV/EBITDA
- 137.02
Profitability & growth
- ROE (TTM)
- 11.0%
- Operating margin
- 74.4%
- Revenue growth YoY
- 3749.0%
- Dividend yield
- —
- Beta
- 1.52
Last earnings
Aug 5, 2026 · Estimate $2.11 · Reported $2.29
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Protagonist Therapeutics Inc
Company profileProtagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 7707 GATEWAY BOULEVARD, NEWARK, CA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$8.33B
Shares outstanding$64.7M
52W high$160.81
52W low$73.08
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent